Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almirall and Forest Laboratories have released ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) Phase III study results of inhaled Aclidinium Bromide 200µg and 400µg, which showed increase in baseline in morning pre-dose (trough) FEV1 versus placebo at week 24, which was the primary endpoint of the study for Europe and at week 12, which was the primary endpoint of the US trial.
Subscribe to our email newsletter
Almirall and Forest said that Aclidinium was well tolerated in the study and all secondary endpoints demonstrated differences vs placebo for both doses.
The Phase III double-blind placebo-controlled pivotal trial compared the safety and efficacy of Aclidinium Bromide 200µg and 400µg twice daily (BID) versus placebo, in 828 patients with moderate to severe COPD.
In the study, Aclidinium showed changes from baseline in trough FEV1 vs placebo at each time-point, which ranged from 77ml to 105ml for Aclidinium 200µg and from 105ml to 140ml for Aclidinium 400µg.
Almirall chairman and CEO Jorge Gallardo said that the results demonstrate that Aclidinium provided consistent bronchodilation and symptom control in COPD patients suffering from this debilitating disease.
"With these results, we anticipate regulatory filings for Aclidinium BID monotherapy this year," Gallardo said.